6,131 Shares in TransMedics Group, Inc. $TMDX Acquired by Bryce Point Capital LLC

Bryce Point Capital LLC purchased a new stake in TransMedics Group, Inc. (NASDAQ:TMDX) during the third quarter, according to the company in its most recent filing with the SEC. The firm purchased 6,131 shares of the company’s stock, valued at approximately $688,000. TransMedics Group comprises 0.8% of Bryce Point Capital LLC’s investment portfolio, making the stock its 4th biggest position.

Several other institutional investors also recently made changes to their positions in TMDX. Intech Investment Management LLC lifted its stake in TransMedics Group by 28.9% during the second quarter. Intech Investment Management LLC now owns 34,389 shares of the company’s stock valued at $4,608,000 after buying an additional 7,713 shares in the last quarter. Nordea Investment Management AB purchased a new position in TransMedics Group during the 3rd quarter valued at about $4,070,000. Peregrine Capital Management LLC lifted its position in TransMedics Group by 16.5% in the 3rd quarter. Peregrine Capital Management LLC now owns 68,406 shares of the company’s stock worth $7,675,000 after buying an additional 9,676 shares in the last quarter. Intrust Bank NA purchased a new stake in shares of TransMedics Group during the 2nd quarter worth about $747,000. Finally, Lisanti Capital Growth LLC lifted its stake in shares of TransMedics Group by 62.0% in the 3rd quarter. Lisanti Capital Growth LLC now owns 56,901 shares of the company’s stock valued at $6,384,000 after purchasing an additional 21,771 shares during the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

TransMedics Group Stock Performance

Shares of NASDAQ TMDX opened at $136.34 on Tuesday. The firm has a market capitalization of $4.66 billion, a price-to-earnings ratio of 55.20 and a beta of 2.06. TransMedics Group, Inc. has a one year low of $62.07 and a one year high of $156.00. The business has a fifty day simple moving average of $132.84 and a 200 day simple moving average of $124.80. The company has a current ratio of 7.69, a quick ratio of 7.13 and a debt-to-equity ratio of 1.43.

Insider Activity at TransMedics Group

In related news, insider Anil P. Ranganath sold 3,000 shares of the stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $145.22, for a total value of $435,660.00. Following the completion of the transaction, the insider owned 13,955 shares of the company’s stock, valued at $2,026,545.10. This represents a 17.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Gerardo Hernandez sold 920 shares of TransMedics Group stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $139.62, for a total value of $128,450.40. Following the sale, the chief financial officer directly owned 15,064 shares in the company, valued at $2,103,235.68. The trade was a 5.76% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 8,920 shares of company stock valued at $1,257,310 over the last quarter. 7.00% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities analysts have commented on TMDX shares. Morgan Stanley increased their price target on TransMedics Group from $123.00 to $135.00 and gave the company an “equal weight” rating in a report on Tuesday, December 2nd. Jefferies Financial Group started coverage on shares of TransMedics Group in a research note on Monday, October 13th. They issued a “buy” rating and a $145.00 target price on the stock. Wall Street Zen downgraded shares of TransMedics Group from a “buy” rating to a “hold” rating in a report on Saturday, January 31st. Needham & Company LLC upped their price target on shares of TransMedics Group from $148.00 to $166.00 and gave the company a “buy” rating in a report on Monday, December 8th. Finally, Piper Sandler reiterated an “overweight” rating on shares of TransMedics Group in a research note on Monday, December 22nd. Six analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, TransMedics Group presently has an average rating of “Moderate Buy” and an average price target of $144.25.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.